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Abstract
Background: Perforated colon cancer is a rare complication, but has a high risk of recurrence. However, most
studies have not distinguished sealed-off perforation from free perforation, and the prognosis is unclear. The aim
of this study was to evaluate the oncologic outcome of colon cancer with sealed-off perforation.
Methods: Eighty-six consecutive patients who underwent resection for colon cancer with sealed-off or free perforation
were included. We defined sealed-off perforation as a colon perforation with localized abscess identified on operative,
computed tomography, or pathologic findings, with no evidence of free perforation, including fecal contamination
and dirty fluid collection in the peritoneal cavity. Oncologic outcomes were compared between patients with colon
cancer with sealed-off perforation and free perforation using a log-rank test and Cox regression analysis.
Results: The sealed-off perforation group included 62 patients, and 24 patients were in the free perforation group.
TNM stage and lymphatic, venous, and perineural invasion were similar between the groups. The median follow-up
period was 28.9 months (range 0–159). The sealed-off perforation group had better prognosis compared with the free
perforation group in terms of progression-free survival (PFS) and overall survival (OS), although there were no
statistically significant differences in PFS (5-year PFS 53.7% vs. 40.5%, p = 0.148; 5-year OS 53.6% vs. 22.9%, p = 0.001).
However, in multivariable analysis using the Cox progression test, sealed-off perforation did not show a significant
effect on cancer progression (p = 0.138) and OS (p = 0.727).
Conclusions: Colon cancer with sealed-off perforation showed no difference in prognosis compared with free
perforation.
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Introduction
The prevalence of perforation in colon cancer patients is
reported to be 3–10% [1–3]. More specifically, colon cancer
patients with perforation exhibit a greater frequency of
recurrence and poorer overall survival (OS) compared
with those without perforation [4, 5]. In the National
Comprehensive Cancer Network guidelines, colon cancer
with perforation is categorized a high-risk feature [6].
Perforations caused by colon cancer appear as free or
sealed-off perforations. A previous study reported that
local inflammation affects the prognosis of colorectal cancer
[7]; therefore, sealed-off perforation is suspected to exhibit
oncological outcomes different from those of free perfor-
ation, due to local inflammation caused by the formation of
localized abscess. Furthermore, unlike cases of free perfor-
ation in which the possibility of tumor dissemination is
high, cases of sealed-off perforation prevent tumor spread
due to the formation of an abscess cavity. Therefore,
sealed-off perforation is expected to have better prognosis
compared with free perforation. To the best of our know-
ledge, no prior study has assessed the prognostic difference
in colon cancer patients with free or sealed-off perforation.
* Correspondence: sowisdom@gmail.com
1Department of Surgery, Seoul National University College of Medicine, 101,
Daehak-ro, Jongno-gu, Seoul, South Korea
2Cancer Research Institute, Seoul National University College of Medicine,
Seoul, South Korea
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lee et al. World Journal of Surgical Oncology          (2018) 16:232 
https://doi.org/10.1186/s12957-018-1530-3
This study divided patients into free and sealed-off groups
to assess differences in baseline characteristics and whether
sealed-off or free perforations have different effects on
oncological outcomes.
Method
Subjects in this study were pathologically diagnosed with
primary colon cancer and received surgical treatment at
Seoul National University Hospital between March 2002
and August 2017. The inclusion criterion was the presence
of either free or sealed-off perforation. The exclusion criteria
were history of other malignancy, other accompanying
malignancy, and endoscopic or stent-related perforation.
We defined sealed-off perforation as a colon perforation
with localized abscess identified on operative computed
tomography or pathologic examination, with no evidence
of free perforation including fecal contamination and dirty
fluid collection in the peritoneal cavity.
Data collected were retrospectively reviewed. Patient
clinical characteristics, operative outcomes, pathologic
examination results, and postoperative chemotherapy,
complications, and mortality were assessed. Complications
were classified using the Clavien-Dindo classification. Pa-
tients without metastasis were assessed for recurrence while
patients with metastasis were assessed for progression.
Study approval was obtained from Seoul National
University Hospital Institutional Review Board (IRB).
Follow-up
The patient was discharged if the following conditions were
met: postoperative vital signs were stable, no abnormalities
were observed on physical examination, no sign of inflam-
mation was observed on laboratory examination, and no
dietary issues were present. Stage II and III patients
were asked to return for follow-up visits every 6 months
for the first 2 years. To detect potential recurrences in
these patients, a carcinoembryonic antigen (CEA) test
was performed every 6months; chest, abdomen, and pelvic
computed tomography (CT) were performed annually, and
colonoscopy was performed every 6–12months. Stage IV
patients attended regular follow-up visits every 3months.
These patients had CEA every 3 months, CT every 3–6
months, and colonoscopy every year to assess possible
recurrence.
Outcome
The primary end-point of this study was progression-free
survival (PFS), and the secondary outcome was local
recurrence-free survival (LRFS), peritoneal recurrence-free
survival (PRFS), and overall survival. PFS was defined as
the time between the date of surgery and the date of
diagnosis, cancer progression, or death from any cause.
LRFS was defined at the time between the date of surgery
and the date of diagnosis of local recurrence, cancer
progression, or death from any cause. PRFS was defined
at the time between the date of surgery and the date of
diagnosis of peritoneal recurrence, cancer progression,
or death from any cause. OS was defined as the time
period between the date of surgery and the date of death
from any cause. When we performed the survival analysis,
patients who died within 30 days after surgery were ex-
cluded to focus on oncologic outcomes.
Statistical analysis
To compare baseline characteristics between the free and
sealed-off perforation groups, the chi-squared test, Fisher’s
exact test, and linear-by-linear association method were
used as categorical variables, while the independent t test
or Mann-Whitney test were used for continuous variables,
based on normality of data.
To compare PFS and OS, the Kaplan-Meier method
(including log-rank test) was used to perform survival
analysis. Cox proportional hazards regression was used
to identify independent factors affecting PFS and OS.
Furthermore, the propensity score matching was per-
formed with 1:1 ratio between two groups using logistic
regression as estimation algorithm and the nearest neighbor
as the matching algorithm. Covariables used in the
matching were age, sex, ASA classification, BMI, stage,
and postoperative chemotherapy.
Statistical tests were performed using the statistical
package for the social sciences (SPSS) version 25.0 for
windows (IBM Corp, Armonk, NY, USA), and p < 0.05
was considered statistically significant.
Results
Of 5823 patients who received surgical treatment for pri-
mary colon cancer at Seoul National University Hospital,
108 had colonic perforation. After excluding patients with
perforations caused by stenting or colonoscopy and those
with perforations distant from the tumor, 86 patients
were included in the final study cohort. Of these, 24
had a free perforation and 62 had a sealed-off perfor-
ation (Fig. 1). The median follow-up was 28.9 months
(range 0–159 months).
Baseline patient characteristics are shown in Table 1.
Patients in the free perforation group were older than
those in the sealed-off perforation group (76.1 ± 12.5 vs.
59.4 ± 15.5 years). In addition, the free perforation group
had more patients with higher American Society of
Anesthesiologists (ASA) class and fewer received post-
operative chemotherapy (29.2% vs. 74.2%). Emergency
operation was performed more frequently in the free
perforation group. (91.7% vs 22.6%, p = 0.000). The rate
of postoperative complications in the free perforation
group was statistically significantly higher than that in
the sealed-off perforation group (Table 1). The duration
of hospital stay was longer in the free perforation group
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than in the sealed-off perforation group, but the differ-
ence was not statistically significant (17.4 ± 14.2 days vs.
12.0 ± 12.3 days, p = 0.062). The 30-day mortality did
not differ statistically but was higher in the free perforation
group than in the sealed-off perforation group (12.5% vs.
1.6%, p = 0.064).
The median PFS durations for the free and sealed-off
perforation groups were 13.8months (range 0–83months)
and 27.9months (range 0–159), respectively, with a 5-year
PFS of 40.5% and 53.7%. The sealed-off perforation group
displayed a better trend in the Kaplan-Meier curve. How-
ever, the log-rank test did not show statistically significant
differences between the groups (p = 0.148) (Fig. 2b). LRFS
and PRFS according to the type of recurrence were ana-
lyzed. Five-year LRFS of 75.8% and 84.0% and 5-year PRFS
of 75.0% and 94.7% were observed between free and
sealed-off perforation groups. The sealed-off perforation
group appeared to have a better prognosis in terms of
LRFS and PRFS (Fig. 2b, c). However, there was no signifi-
cant difference between the two groups in the log-rank
test (LRFS, p = 0.315; PRFS, p = 0.069).
The median OS durations for the free and sealed-off
groups were 19.6 months (range 0–84) and 49.3 months
(range 0–181) respectively, with a 5-year OS of 22.9%
and 53.6%. The sealed-off perforation group appeared to
have a better prognosis (Fig. 2d). There was a significant
difference between the two groups in the log-rank test
(p = 0.001).
Cox proportional hazards regression was performed to
identify the factors associated with cancer progression.
Several factors including ASA class 3 (p = 0.024), tumor
size (p = 0.005), and T stage (p = 0.043) affected cancer
progression, but sealed-off perforation did not show a
significant effect on cancer progression (p = 0.138)
(Table 2).
In an analysis to identify risk factors for OS, ASA class
(p = 0.011) and major postoperative complications (p =
0.049) were statistically significant. However, the pres-
ence of sealed-off perforation was not a factor affecting
OS (p = 0.727) (Table 3).
We performed propensity score matching by adjusting
for age, sex, ASA class, BMI, stage, and postoperative
chemotherapy between the two groups (Additional file 1:
Table S1). However, there was no difference in PFS
(p = 0.604), LRFS (p = 0.919), PRFS (p = 0.323), and OS
(p = 0.062) between the two groups (Additional file 2: Fig-
ure S A-D). Furthermore, the perforation type did not ap-
pear to be a factor affecting PFS (HR 0.565, 95% CI
0.000–1500.805) and OS (HR 12.930, 95% CI 0.131–
1053.246) (Additional file 1: Tables S2 and S3).
Discussion
This study demonstrated that primary colon cancer patients
with sealed-off perforation did not have a better prognosis
in PFS and OS compared to patients with free perforation,
although the Kaplan-Meier curves with log rank test for
overall survival showed a statistically significant difference.
Perforation type was not a risk factor for PFS and OS
although propensity score matching was performed to
correct the differences in baseline characteristics between
the two groups.
Colon cancer perforation is known to have a poor
prognosis, not only because it frequently occurs in ad-
vanced stage cancers but also because perforation itself
Fig. 1 Flow chart of patient selection
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Age (years old) 76.1 ± 12.5 59.4 ± 15.5 0.000
Sex 0.874
Male 14 (58.3%) 35 (56.5%)
Female 10 (41.7%) 27 (43.5%)
BMI (kg/m2) 22.7 ± 3.5 22.0 ± 2.8 0.458
ASA class 0.001
1 4 (19.0%) 26 (44.8%)
2 8 (38.1%) 26 (44.8%)
3 8 (38.1%) 6 (10.3%)
4 1 (4.8%) 0 (0%)
Surgery 0.000
Elective 2 (8.3%) 48 (77.4%)
Emergency 22 (91.7%) 14 (22.6%)
Operation intent 0.752
Curative 19 (79.2%) 52 (83.9%)
Palliative 5 (20.8%) 10 (16.1%)
Tumor differentiation 0.858
Adenocarcinoma, well differentiated 1 (4.2%) 3 (4.8%)
Adenocarcinoma, moderate differentiated 19 (79.2%) 48 (77.4%)
Adenocarcinoma, poorly differentiated 3 (12.5%) 8 (12.9%)
Mucinous carcinoma 1 (4.2%) 2 (3.2%)
Signet ring cell carcinoma 0 (0.0%) 1 (1.6%)
Size (cm) 5.8 ± 2.3 6.6 ± 2.3 0.100
pT 0.687
3 12 (50.0%) 28 (45.2%)
4 12 (50.0%) 34 (54.8%)
pN 0.779
0 10 (41.7%) 27 (43.5%)
1 11 (45.8%) 23 (37.1%)
2 3 (12.5%) 12 (19.4%)
The number of metastatic LN 1.5 ± 2.9 2.2 ± 3.8 0.325
The number of harvest LN 18.9 ± 9.5 23.3 ± 11.4 0.091
M 0.588
0 16 (66.7%) 45 (72.6%)
1 8 (33.3%) 17 (27.4%)
Proximal margin (cm) 27.5 ± 30.2 19.5 ± 20.4 0.088
Distal margin (cm) 13.9 ± 14.5 10.7 ± 9.5 0.395
Lymphatic invasion 0.848
Absent 13 (54.2%) 35 (56.5%)
Present 11 (45.8%) 27 (43.5%)
Venous invasion 0.161
Absent 15 (62.5%) 45 (77.6%)
Present 9 (37.5%) 13 (22.4%)
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Absent 17 (70.8%) 37 (63.8%)
Present 7 (29.2%) 21 (36.2%)
Postoperative complication
(Clavien-Dindo classification) 0.000
No complication 9 (37.5%) 50 (42.5%)
Grade I 2 (8.3%) 0 (0%)
Grade II 4 (16.7%) 8 (12.9%)
Grade III 5 (20.8%) 3 (4.8%)
Grade IV 4 (16.7%) 1 (1.6%)
Postoperative chemotherapy 7 (29.2%) 46 (74.2%) 0.000
BMI body mass index, ASA class American Society of Anesthesiologists classification, LN lymph nodes
Fig. 2 Kaplan-Meier curves between sealed-off (green line) and free perforation (blue line). a Progression-free survival. b Local recurrence-free
survival. c Peritoneal recurrence-free survival. d Overall survival
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can cause septic complications [2]. More specifically,
tumor perforation can cause tumor dissemination, leading
to greater recurrence rate and poorer survival [8]. We
expected that sealed-off perforation would result in less
dissemination of malignant cells into the peritoneal cavity.
However, the difference in PFS between the groups was
not statistically significant. Even local recurrence and
peritoneal recurrence were not different from each other.
This may be due to the smaller number of patients in the
free perforation group. In addition, patients in the sealed-
off perforation group may exhibit tumor dissemination if
the abscess cavity bursts during surgery. However, we
could not assess possible rupture of an abscess cavity
during dissection, which may have led to statistically
non-significant outcomes. Furthermore, better trends
for LRFS, PRFS, and PFS were observed in the sealed-off
perforation group, although the pathologic findings (TNM
stage, and lymphatic, venous, and perineural invasion)
were not different between the groups, suggesting that
perforation type may affect prognosis.
Although several studies reported the effects of inflam-
mation in the local tumor environment [9–11], the effect
of sealed-off perforation on local inflammation has not
been sufficiently addressed. This study is the first to assess
the difference in oncological prognosis between sealed-off
perforation and free perforation. Nonetheless, additional
studies should be performed to assess the differences in
local immunity according to perforation types.
In the analysis of risk factors affecting cancer pro-
gression, T stages were a risk factor, but not N stages.
We suspect that N stages could not be identified as risk
factors because of the small number of enrolled patients.
Poorer OS in the free perforation group compared to
the sealed-off perforation group is likely due to older
age, greater frequency of comorbidities, and postopera-
tive morbidity. Univariable analysis for OS further
supports this hypothesis. The baseline characteristics of
free perforation patients were older age, greater frequency
of comorbidity, and lower frequency of postoperative
chemotherapy. Therefore, we could not narrow the
Table 2 Risk factors associated with cancer progression
Hazard ratio 95% confidence interval p value
Age (years old) 0.986 0.940–1.033 0.545
Sex (female) 2.039 0.677–6.141 0.205
ASA class 0.057
1 1 (reference) 1 (reference)
2 0.914 0.237–3.523 0.897
3 8.192 1.313–51.120 0.024
BMI (Kg/m2) 1.079 0.888–1.310 0.444
Sealed-off perforation 0.443 0.151–1.300 0.138
Emergency operation 0.082 0.008–0.864 0.037
Palliative 2.867 0.423–19.450 0.281
Size(cm) 1.483 1.074–2.046 0.017
pT 0.012
3 1 (reference) 1 (reference)
4 10.657 1.669–68.028
pN 0.697
1 0.603 0.170–2.139 0.434
2 0.606 0.096–3.816 0.594
M1 4.594 0.838–25.197 0.079
Proximal margin (cm) 1.041 1.002–1.082 0.038
Distal margin (cm) 0.949 0.887–1.016 0.134
Lymphatic invasion 1.535 0.514–4.568 0.444
Venous invasion 1.382 0.340–5.626 0.651
Perineural invasion 1.193 0.276–5.150 0.813
Postoperative chemotherapy 3.376 0.622–18.322 0.159
Postoperative major complication† 5.628 0.991–31.970 0.051
BMI body mass index, ASA class American Society of Anesthesiologists classification
†Clavien-Dindo classification grade 3 or higher was defined as major complication
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difference between two groups even after propensity
score matching.
Postoperative chemotherapy was performed signifi-
cantly more often in the sealed-off perforation group.
Relatively higher ASA class and older age of patients in
the free perforation group can explain this finding.
There were several limitations in this study. First, the
retrospective design may have introduced selection bias
and possibly some errors during data extraction. Second,
type II error is a possibility since the number of patients
with free perforation was smaller than the number with
sealed-off perforation.
In conclusion, colon cancer with sealed-off perforation
showed no difference in prognosis compared with free
perforation even after propensity score matching was per-
formed. Considering the limitations of a small number of
patients and unbalanced patient distribution, additional
studies with larger cohort should be performed to assess
the effect of sealed-off perforation on local immunity.
Additional files
Additional file 1: Table S1 Clinicopathologic characteristics after
propensity score matching. Table S2 Risk factors associated with cancer
progression after propensity score matching. Table S3 Risk factors for
overall survival after propensity score matching. (DOCX 21 kb)
Additional file 2: Kaplan-Meier curves between sealed-off (green line)
and free perforation (blue line) after propensity score matching. (a) local
recurrence-free survival. (b) peritoneal recurrence-free survival. (c)
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Table 3 Risk factors for overall survival
Hazard ratio 95% confidence interval p value
Age (years old) 1.034 0.998–1.071 0.068
Sex (female) 0.839 0.350–2.012 0.694
BMI (kg/m2) 0.927 0.811–1.059 0.265
ASA class 0.011
1 1 (reference) 1 (reference)
2 0.465 0.16–1.320 0.150
3 3.503 0.977–12.563 0.054
Sealed-off perforation 0.759 0.162–3.554 0.727
Emergency operation 0.694 0.171–2.812 0.609
Palliative 2.340 0.520–10.532 0.268
Size (cm) 0.886 0.724–1.084 0.239
pT 0.025
3 1 (reference) 1 (reference)
4 3.480 1.174–10.318
pN 0.546
0 1 (reference) 1 (reference)
1 1.029 0.430–2.461 0.950
2 2.168 0.538–8.747 0.277
M1 4.766 1.432–15.860 0.011
Proximal margin (cm) 1.009 0.986–1.032 0.440
Distal margin (cm) 1.013 0.972–1.057 0.535
Venous invasion 1.013 0.246–2.199 0.583
Lymphatic invasion 1.541 0.614–3.862 0.357
Perineural invasion 2.225 0.754–6.569 0.148
Postoperative chemotherapy 0.562 0.188–1.677 0.302
Postoperative major complication† 3.931 1.009–15.319 0.049
BMI body mass index, ASA class American Society of Anesthesiologists classification
†Clavien-Dindo classification grade 3 or higher was defined as major complication
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